<DOC>
	<DOCNO>NCT03004339</DOCNO>
	<brief_summary>Evaluation safety , pharmacokinetics , anti-psoriatic efficacy ass SOR007 Ointment topical formulation</brief_summary>
	<brief_title>Trial Assess Potency SOR007 Ointment Psoriasis Plaque Test</brief_title>
	<detailed_description>This two-center , randomize , placebo- active comparator-controlled trial double-blind investigational product ( IPs ) observer-blind active comparator intra-individual comparison treatment . Twelve male post-menopausal female volunteer subject , age 18 year old , psoriasis vulgaris mild moderate chronic plaque ( ) stable phase area sufficient six treatment field , enrol . SOR007 Ointment administer topically four concentration ( 0.15 % , 0.3 % , 1 % , 2 % ) , addition placebo ointment ( SOR007 without active pharmaceutical ingredient ) active comparator , Taclonex® Ointment ( calcipotriene 0.005 % betamethasone dipropionate 0.064 % ) . Treatments administer daily , 10 time 12-day trial period . Assessments include safety , pharmacokinetics ( PK ) , preliminary efficacy determine measurement psoriatic infiltrate use 22-megahertz ( MHz ) sonography well clinical score 5-point scale . Subjects withdraw early reason unrelated investigational product adverse event ( AEs ) replace .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>men surgically sterile postmenopausal ( least since 12 month amenorrhoea ) woman age 18 year old . The nonchildbearing potential woman need confirm medical record write gynecologist , possible follicle stimulate hormone ( FSH ) test perform female subject confirm menopause , unless receive hormonal replacement therapy treatment menopause symptom ; subject psoriasis vulgaris chronic stable phase mild moderate plaque ( ) three plaque area sufficient six treatment field ; target lesion ( ) trunk extremity ( exclude palms/soles ) ; psoriatic lesion knee elbow use target lesion ; plaque treat comparable psoriatic infiltrate thickness least 200 μm ; physical examination skin must without disease finding psoriasis vulgaris unless investigator considers abnormality irrelevant outcome clinical trial ; male volunteer must agree sexual abstinence use adequate contraception sexually active combination female partner , childbearing potential . That mean volunteer must vasectomize use condom female partner must either surgically sterile ( hysterectomy tubal ligation ) agree use reliable method contraception failure rate le 1 % per year use consistently correctly implant , injectables , combine oral contraceptive , nonDalKon Shield intrauterine device [ IUDs ] . This apply sign inform consent form 90 day last study drug administration . Methods contraception must effective least 30 day day sign informed consent form . Male volunteer must also refrain sperm donation signing informed consent form 90 day last study drug administration ; write informed consent obtain . pregnancy nursing ; skin disease condition note physical examination consider investigator relevant outcome trial ; subject acute psoriasis guttata , psoriasis punctata , psoriasis erythrodermatica pustular psoriasis ; topical antipsoriatics plaque potentially treat trial ( include corticosteroid , vitamin D analogue , immunomodulators , retinoids , dithranol tar , except salicylic acid except treatment face , ears scalp ) 4 week first treatment and/or trial ; systemic treatment antipsoriatics e.g . corticosteroid , cytostatics , retinoids , dimethylfumarate three month first treatment trial ; systemic treatment biological treatment : ustekinumab secukinumab within six month adalimumab , infliximab etanercept within three month first treatment trial ; UVtherapy within four week first treatment trial ; treatment systemic locally act medication might counter influenced trial aim ( medication know provoke aggravate psoriasis , e.g . antimalarial drug , lithium ) within eight week first treatment and/or trial . Betablockers angiotensinconverting enzyme ( ACE ) inhibitor allow stable dose 3 month study medication initiation ; intake Anticoagulant Drugs , e.g . Warfarin , Coumadin . Antiplatelet Drugs e.g . Acetyl salicylic acid permit unless consider contraindicated investigator blood withdrawal PK analyse ; know allergic reaction , irritation sensitivity active ingredient component IPs ; know allergic reaction , irritation sensitivity comparator 's active ingredient and/or component ; contraindication accord summary product characteristic active comparator ; evidence drug alcohol abuse ; symptom clinically significant illness may place subject risk trial participation influence outcome trial four week first treatment trial ; participation treatment phase another clinical trial within last four week prior first treatment clinical trial ; opinion investigator physician perform initial examination subject participate trial , e.g . due probable noncompliance inability understand trial give adequately informed consent ; close affiliation investigator ( e.g . close relative ) person work bioskin GmbH Modoc subject employee sponsor ; subject institutionalized legal regulatory order .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>